Stefano Del Prato on Muck Rack

Stefano Del Prato

Italy
As seen in: Color Research & Application, Nature, Wiley, Wiley Online Library, Memory Studies, The Lancet, EURACTIV, MedPage Today, Endocrine Today, Diabetes Care Magazine and
Diabetologist. Professor of Endocrinology, @Unipisa. Past-President @EASD. President European Diabetes Forum @EUDF. Honorary president @Sid_Italia.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Stefano

Contact Stefano, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

International Conference on Advanced Technologies and Treatments for Diabetes

|
By Michael Monostra Verified, Richard Smith, Stefano Del Prato
| Citeline Verified
Key takeaways: Adults with recently diagnosed type 2 diabetes had a greater decline in HbA1c with tirzepatide than with conventional care. At 2 years, 60.2% of the tirzepatide group attained an HbA1c of less than 5.7%. Tirzepatide provided a larger reduction in HbA1c and greater improvements in multiple cardiometabolic parameters compared with conventional care for adults recently diagnosed with type 2 diabetes, according to a speaker.
Open in Who Shared Issue with article?

Additional benefits of combining GLP-1 receptor agonist use with lifestyle modification

|
By Stefano Del Prato, Anna Solini
| The Lancet Verified
Get full text access Log in, subscribe or purchase for full access. References 1. Lee, MMY ∙ Sattar, N ∙ Pop-Busui, R ∙ et al., the SOUL Trial Investigators Cardiovascular and kidney outcomes and mortality with long-acting injectable and oral glucagon-like peptide 1 receptor agonists in individuals with type 2 diabetes: A systematic review and meta-analysis of randomized trials Diabetes Care. 2025; 48:846-859 2. Connolly, D ∙ Collins, E ∙ Ren, H ∙ et al.
Open in Who Shared Issue with article?

Diabetes community calls for quality standards for continuous glucose monitoring devices

|
By Francesco Giorgino, Stefano Del Prato
| The Lancet Verified
Continuous Glucose Monitoring (CGM) devices are increasingly used by people living with diabetes (PwD) and contribute to a more personalised and effective diabetes care, leading to improved glycaemic control impacting diabetes-related complications. Their use is increasing in Europe, and many new manufacturers are coming to the market. CGMs, tracking in real-time glucose levels, are a key tool for PwD and their healthcare teams in the daily diabetes management.
Open in Who Shared Issue with article?
See all 42 licensed articles (46 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified